BRISBANE, Calif., April 28, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the first quarter ended March 31, 2011. InterMune also highlighted its recent clinical development and business activities.
Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "First quarter events were highlighted by the announcement on March 3 that the European Commission had granted marketing authorization for Esbriet® (pirfenidone) for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis, or IPF. The approval of Esbriet not only marks an historic moment in the treatment of IPF patients, but also an exciting new chapter for our company as we now transition to become an international commercial organization. We are working diligently to make Esbriet available to European patients as soon as possible, beginning with Germany in September of this year."
Mr. Welch continued, "In March we met with the U.S. FDA to discuss our plan to conduct an additional Phase 3 study of pirfenidone, toward the goal of bringing pirfenidone to IPF patients in the United States. We plan to conduct an Analyst Day in New York on May 26 to provide a comprehensive update of our commercial and scientific plans. During this event we will provide details on ASCEND -- our new Phase 3 study -- including the study design, its scientific rationale and guidance on important study and NDA resubmission milestones. At that time we will also share our expense guidance for 2011."
InterMune commented, in response to speculation in recent press reports that the management and Board are very enthusiastic about the company's business plans and the company is not currently in discussions regarding a sale of the company.
Clinical Development, Business Highlights a
|SOURCE InterMune, Inc.|
Copyright©2010 PR Newswire.
All rights reserved